



Wilex (Munich) has announced that **Paul Bevan**, formerly research director at Xenova Therapeutics and a member of Xenova Group's executive board,

has been appointed the company's head of research and development and a member of the executive board. Dr. Bevan was most recently CEO of PharmAssociates, a pharmaceutical consulting firm that he founded in 1999.

Stéphane Boissel has been appointed chief financial officer at Innate Pharma (Marseille, France). Mr. Boissel has spent the past seven years with Groupe Lazard in France, Singapore, and Hong Kong, and was most recently director of investments at Eurazeo, a member of the Lazard group.

Joseph R. Chinnici has been elected to the board of directors at Guilford Pharmaceuticals (Baltimore, MD), as well as to the board's audit committee. He currently serves as senior vice president, finance and CFO at CIENA Corp. Mr. Chinnici replaces **David P. Wright**, who recently resigned his position on Guilford's board.

Juvaris BioTherapeutics (Pleasanton, CA), a privately held therapeutic vaccine company, has announced the appointment of **Martin D. Cleary** as chairman, president, and CEO. From 1999 to 2002, Mr. Cleary served as president, CEO, and a director of Genteric, and was previously cofounder, president, and CEO of CardioGene Therapeutics.

PhageTech (Montreal, QC, Canada) has named **Daniel Delorme**, formerly vice president of medicinal chemistry at MethylGene, as vice president of chemistry. Prior to joining MethylGene in 1998, Dr. Delorme was associate director of medicinal chemistry at AstraZeneca (Montreal). PhageTech also announced the appointment of **Michel Harpin**, formerly senior marketing advisor of life sciences at Solidarity Fund QFL, as director of business development.

Odyssey Thera (San Ramon, CA) has named **Louis Ignarro** to its board of directors. Dr. Ignarro is a professor in the department of molecular and medical pharmacology at the UCLA School of Medicine and recipient of the 1998 Nobel Prize in Physiology or Medicine.

John W. Kozarich has been elected to the board of directors of Ligand Pharmaceuticals (San Diego, CA). Dr. Kozarich is president, CEO, and CSO of

ActivX Biosciences, and was previously vice president at Merck Research Laboratories. In addition, Dr. Kozarich is a biotechnology professor at the Scripps Research Institute.

Ortec International (New York) has announced the promotion of **Ron Lipstein** to the position of CEO. Mr. Lipstein is a founder of Ortec and has served as CFO since its inception and as vice chairman for the past two years. He will continue in his role as vice chairman. In addition, **Costa Papastephanou**, president of Ortec, will also assume the position of COO. **Steven Katz**, who has served as CEO since Ortec's founding, will continue to serve as chairman of the board.

Aton Pharma (Tarrytown, NY) has announced the appointment of **Carolyn M. Paradise** as senior vice president and chief medical officer. Dr. Paradise previously served as executive vice president, clinical operations and regulatory affairs and chief medical officer at Cell Therapeutics.

Nabi Biopharmaceuticals (Boca Raton, FL) has named **Henrik Rasmussen** to the position of vice president, clinical and regulatory affairs, a newly created position. Dr. Rasmussen joins the company from GenVec, where he was senior vice president of clinical and regulatory affairs. Prior to that, he was senior vice president of clinical research and regulatory affairs at British Biotech.

Lauren P. Silvernail has joined ISTA Pharmaceuticals (Irvine, CA) as CFO and vice president of corporate development. Prior to joining the company, Ms. Silvernail spent eight years at Allergan, most recently as vice president of business development.

Auxilium Pharmaceuticals (Norristown, PA) has named **Stephen G. Sudovar**, president and CEO of EluSys Therapeutics and former president of Roche Laboratories, to its board of directors.

William Spickler has joined Angiogenix (Burlingame, CA) as vice president of pharmaceutical development. Most recently, he served as the senior medical director for XOMA, where he was responsible for clinical development programs in the cardiovascular and rheumatology therapeutic areas.

Doug Williams has been appointed chairman of the board of directors of startup Amnis (Seattle, WA). Previously executive vice president and chief technology officer at Immunex, Dr. Williams became senior vice president, Washington site leader for Amgen upon its acquisition of Immunex. He has been a member of Amnis's board since 2000.